John de Kruif has served at Merus NV, a clinical stage company working on targeted treatments to address the unmet needs of patients with various types of cancer, as their Chief Technology Officer since January 2013 where he previously served as their Chief Scientific Officer from April 2007 to January 2013. His responsibilities include management of antibody discovery, antibody developability and antibody engineering. Before joining Merus, from October 2000 to October 2006, he served as a director of antibody discovery for Crucell N.V., a biotechnology company specializing in vaccines and biopharmaceutical technology. John holds a PhD in Antibody Engineering from Utrecht University.